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Introduction
Thrombocytopenia is, after anemia, the most common hematological disorder in neonates, affecting 20-30% of infants admitted to the Neonatal Intensive Care Unit [1] . In 25% of affected neonates, the platelet count drops below 50 9 10 9 L À1 [2] , and 9% of those infants experience clinically significant bleeding (most commonly intracranial) [3] . Platelet transfusions are frequently given to neonates with these (and milder) degrees of thrombocytopenia, in an attempt to prevent bleeding [4] . In approximately 10% of affected infants, the thrombocytopenia persists for > 30 days [5] and leads to multiple platelet transfusions (> 20) [6] . For some of these patients, thrombopoietin mimetics such as romiplostim and eltrombopag (ELT) may offer an opportunity to raise the platelet count pharmacologically, thus reducing platelet transfusions. Eltrombopag has the advantage of being an oral thrombopoietin mimetic and is FDA approved for the treatment of adults with chronic immune thrombocytopenic purpura (ITP), thrombocytopenia associated with chronic hepatitis C and aplastic anemia. In 2015, the FDA approved ELT for use in children with ITP not responsive to first-line therapies, largely based on the positive results of PETIT2, a randomized placebo controlled trial that enrolled children aged 1-17 years [7] . Recent publications have reported the successful use of ELT in adult and pediatric patients with other hematological disorders, including inherited thrombocytopenia associated with MYH9 mutations [8, 9] WiskottAldrich syndrome [10] and aplastic anemia. Thus, it is likely that ELT will soon be considered as a therapeutic alternative in neonates, infants and children in the first year of life with different varieties of thrombocytopenia. In that population, it is important to consider the potential for non-hematologic developmental stagespecific effects.
In 2012, Roth et al. showed that ELT is a potent intracellular iron chelator, and that its ability to reduce intracellular iron in leukemic cells leads to decreased proliferation and induction of differentiation of these cells [11] . Leukemic cells are highly metabolic cells and thus have high iron requirements to support their mitochondrial oxidative metabolism.
The neonatal and early postnatal brain also has high iron requirements related to its high metabolic rate [12, 13] . Sixty percent of a newborn's total body oxygen consumption is attributable to the brain [14] . Iron uptake is avid in the neonatal period [12] to support this high metabolic rate, which derives largely from the rapid growth, differentiation and myelination of neurons. Neuronal dendrite maturation (i.e. dendrite growth/branching and spine and formation) is critical to the formation of functional neural circuits [15] . Developing neurons in the hippocampus, a brain region important for declarative learning/memory processing, have particularly high iron requirements because they are among the most metabolically active cells in the neonatal period [16, 17] .
Iron deficiency (ID) is particularly deleterious during this early lifetime period (i.e. the fetus, infant and toddler), causing neurodevelopmental deficits in motor, social, learning/memory and attention domains. These neurodevelopmental impairments often persist into adolescence and adulthood despite prompt iron repletion during infancy, and these findings are supported experimentally in rodent models of fetal/neonatal ID [18] . Fetal/neonatal hippocampal neuron-specific ID without anemia leads to a permanently abnormal pyramidal neuron dendrite structure, which is thought to be responsible for the impaired electrophysiology and spatial learning/ memory in adult rodents [19] [20] [21] . Thus, agents that induce neuronal iron loss during development may impair iron-dependent neuronal structural and functional development across the lifespan.
Here, we demonstrate that exposing cultured primary hippocampal neurons to ELT for 7 days generates a similar degree of ID as documented in rodent models of dietary ID and in iron-deficient human neonates. ELTtreated neurons had impaired mRNA expression of genes involved in dendrite/synapse development (e.g. BdnfVI, Camk2a and Vamp1), and an overall reduction in dendritic arborization that was similar to that seen in neurons treated with the iron chelator deferoxamine (DFO). In a separate set of experiments, we demonstrate that ELT crosses an in vitro endothelial cell culture model of the BBB in a time-dependent manner, suggesting in vivo neurons could be at risk from systemically delivered ELT. Together, these data suggest that early-life treatment of thrombocytopenia with ELT may adversely affect irondependent neuronal development.
Materials and methods

BBB culture and ELT uptake assay
In vitro BBB model For the cell culture model of the BBB, primary bovine brain microvascular endothelial cells (BMVEC, Cell Applications Inc., San Diego, CA, USA) were grown in complete growth medium under 5% CO 2 at 37°C. Cells were grown to confluence on 0.4-lm porous filters in transwells (Corning Life Sciences #3460, Tewksbury, MA, USA) that were pretreated with attachment growth factor (Cell Applications Inc.). The media was then replaced with serum-free media containing 138 nM hydrocortisone (Sigma-Aldrich, St. Louis, MO, USA) for 72 h before beginning the transport assay.
Transport of ELT across the BBB Fresh serum-free medium was added to the basal chamber at the beginning of the experiment. Serum-free medium was also prepared with 12.5 lM (equivalent to 6.25 nmol) ELT (Selleck Chemicals #S2229, Houston, TX, USA) and 10 lM RITCDextran (70 kD, Sigma), then added to the apical chamber. The RITC-Dextran is present to monitor tight junction integrity and evidence of paracellular transport because Dextran is not transcytosed when tight junctions are intact. The concentration of ELT used in the transport studies was determined empirically from cytotoxicity studies. The concentration chosen was 50% below that found to be toxic over 24 h (data not shown). Aliquots from the apical and basal chambers were collected at 0 and 24 h after the start of the study. Additional aliquots at 3 and 6 h after the start of the study were taken from the basal chamber to monitor ELT transport over the 24-h time period. The aliquots were analyzed for basal chamber RITC-Dextran accumulation in a fluorescence plate reader (Spectra Max Gemini, Molecular Devices, Sunnyvale, CA, USA). ELT was then detected in the basal chamber media samples by HPLC.
Hippocampal neuronal cell culture experiments
Animals Mice were given free access to food and drinking water and were housed at constant temperature and humidity on a 12-h light : dark cycle. All animal procedures were conducted in facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and in accordance with the principles and procedures outlined in the NIH Guide for the Care and Use of Laboratory Animals. The local Institutional Animal Care and Use Committee approved these procedures.
Primary neuron and glia cultures ( Fig. 1 ) Timed-pregnant CD1 mice were ordered from Charles River Laboratories (Wilmington, MA, USA). Primary hippocampal neuron cultures were prepared from embryonic day 16 embryos as previously described [22] . At 3 days in vitro (DIV), cultures were treated with 67.5 lM 5-fluoro-2 0 -deoxyuridine (Sigma-Aldrich #F0503)/136 lM uridine (Sigma-Aldrich #U6381) (5-FU) to inhibit glia proliferation, allowing a nearly pure neuronal culture. At 7 DIV, half of the media was removed and replaced with fresh glia-conditioned neuronal growth media containing 5-FU and either ELT (Selleck Chemicals #S2229) to a final concentration of 2, 6 or 30 lM, deferoxamine (DFO, Cayman Chemicals #14595, Ann Arbor, MI, USA) to a final concentration of 10 lM, or 0.2% DMSO (vehicle control) ( Fig. 1 ). Cultures were assessed daily for viability and the 30-lM ELT group was terminated at 10 DIV because of cell death. The remainder were analyzed at 14 DIV during the period of peak branching and synapse formation [23] . Postnatal glia cultures for neuronal media conditioning were prepared as previously described [22] .
mRNA expression analysis Total RNA extraction, cDNA synthesis and quantitative real-time polymerase chain reaction (qPCR) were performed on 14 DIV cultures as previously described [22] . TaqMan qPCR probes for the genes assessed are described in Table S1 . Relative mRNA levels for the genes of interest were calculated relative to an internal calibrator cDNA sample and were normalized to a reference gene, TATA box binding protein, Tbp.
Neuronal transfection, immunocytochemistry and dendrite morphology The 6 lM ELT-treated, 10 lM DFO-treated and vehicle-treated control neurons were assessed for neuronal morphology at 14 DIV. For neuronal tracing experiments, an hrGFP-expressing plasmid was electroporated into hippocampal cells prior to plating using a Lonza Nucleofector II system and the Mouse Neuron Nucleofector kit (Lonza, Basel, Switzerland) as previously described [24] . Electroporated cells were then mixed 1 : 1 with nonelectroporated cells before plating. At 14 DIV, cultures were fixed and immunocytochemistry was performed for hrGFP and MAP2 (a dendrite specific protein) with a DAPI (4 0 ,6-diamidino-2-phenylindole) nuclear stain as previously described [22] . Dendrite morphological analysis was performed using manual dendrite tracing and Sholl analyses. ImageJ or FIJI was used for all image processing and morphological analyses [25, 26] . Dendrites were traced using the NeuronJ plugin (http://www.imagescie nce.org/meijering/software/neuronj/) and quantified using XL-Calculation as previously described [24, 27] . Semiautomated Sholl analysis [28] was performed on the NeuronJ tracings using the Sholl Analysis plugin (http://fiji. sc/Sholl_Analysis).
Statistical analysis
Statistical analyses and data graphing were carried out using Prism (GraphPad Software, La Jolla, CA, USA) software. For each analysis, data from two to three independent cultures were pooled. Statistical differences between experimental groups were determined using oneway ANOVA and Tukey's post-hoc multiple comparison test (mRNA expression and dendrite tracing experiments), two-way ANOVA and Tukey's post-hoc multiple comparison test (Sholl analysis) or two-way ANOVA and Bonferonni's post-hoc multiple comparison test (BBB uptake experiments). When variances were unequal (mRNA expression experiments), the Kruskal-Wallis non-parametric test and Dunn's multiple comparison were used. All data are presented as mean AE standard error of the mean (SEM). An a = 0.05 was chosen to define significant differences.
Results
BBB permeability
To determine the ability of ELT to cross BBB endothelial cells, an in vitro brain microvascular endothelial cell model was used. A total of 6.25 nmol ELT was added to the apical chamber and ELT accumulation in the basal chamber was monitored over a 24-h time-course. ELT crossed the modeled BBB in a continuous, time-dependent manner (Fig. 2 ). Up to 24 h, ELT continued to cross the BBB despite no significant increase in RITC-Dextran accumulation in the basal chamber (data not shown). At 24 h, there was 0.1743 nmol of ELT in the basal chamber, which represents transport of 2.79% of the total starting drug in the apical chamber.
Gene expression indexing iron status and neuron development
To determine the effect of ELT and DFO on cellular iron status, qPCR was performed at 14 DIV for two genes that regulate neuronal iron uptake, Tfr1 and Slc11a2. mRNA levels for these genes are regulated through ironregulatory proteins binding to iron-response elements and stabilizing the mRNA in times of cellular iron deficit [29] . ELT at 2 and 6 lM increased Tfr1 mRNA levels by 59% and 65%, respectively, compared with untreated hippocampal cultures. Tfr1 mRNA levels were 67% higher in neurons treated with 10 lM DFO, compared with controls (Fig. 3A) . ELT at 2 and 6 lM, as well as 10 lM DFO, also increased Slc11a2 mRNA levels (Fig. 3B) , although to a lesser extent than Tfr1. This Tfr1 and Slc11a2 response is consistent with functional cellular ID [22, 29, 30] .
Six micromolar ELT and 10 lM DFO reduced mRNA levels for genes indexing neurodevelopment and synaptic plasticity/function to a similar degree (Fig. 4) . (Fig. 4) .
Hippocampal pyramidal neuron dendrite morphology
To enable dendrite tracing of individual neurons, cultures treated with 6 lM ELT, 10 lM DFO or vehicle control were electroporated with an hrGFP-expressing plasmid at 0 DIV and fluorescent immunocytochemistry was performed for MAP2, a dendrite-specific marker (Fig. 5) . Representative images of hrGFP-labeled ( 2 . Eltrombopag (ELT) crosses the blood-brain-barrier. ELT transport assays were performed using primary bovine brain microvascular endothelial cells grown in transwells. 6.25 nmol ELT was placed in the apical chamber and ELT in the basal chamber was measured at 0, 3, 6 and 24 h by HPLC. RITC-labeled dextran was placed in the apical chamber and was measured in the apical and basal chambers at 0 and 24 h as a control for the integrity of the tight junctions. The levels of ELT found in the basal chamber progressively increased, suggesting that the drug passes in a time-dependent manner. Data are presented as mean AE SEM. Asterisks indicate statistically significant differences (P < 0.05) in basal chamber ELT concentration as determined by two-way ANOVA and Bonferonni's post-hoc multiple comparison test.
A, E and I) and MAP2-stained (Fig. 5 , Panels B, F and J) hippocampal neurons are shown along with the corresponding hrGFP/MAP2 merged images (Fig. 5 , Panels C, G and K) and dendrite tracings (Fig. 5 , Panels D, H and L). Consistent with our previous findings in iron-deficient neurons [22] , Sholl analysis (Fig. 6A ) revealed a decrease in overall dendritic arbor complexity with significantly fewer crossings between 50 and 150 lm (except at 70 lm) from the soma in DFO-treated neurons (Fig. 6B) . Treatment with 6 lM ELT significantly decreased the number of crossings between 50 and 190 lm, indicating a slightly more pronounced reduction in dendrite arborization compared with the DFO group.
To distinguish between effects on dendrite formation, growth and branching, detailed analysis of dendrite tracings was performed. Consistent with the Sholl analysis data, the sum length of all dendrites (an indication of the total dendrite output and thus ability to form synaptic connections) was significantly lower in both ELT-and DFO-treated neurons (Fig. 6C ). ELT and DFO both reduced the sum length of all branches by 42% and 23%, respectively (Fig. 6D) . Hippocampal pyramidal neurons have two types of primary dendrites: a single, long major dendrite extending from the cell apex (i.e. apical dendrite) and several short minor dendrites extending from the cell base (i.e. basal dendrites). As an in vitro surrogate for Fig. 3 . Eltrombopag (ELT) causes neuronal iron deficiency. Hippocampal neuron cultures were treated with ELT or deferoxamine at 7 days in vitro (DIV) (see Fig. 1 ). At 14 DIV, cells were collected, total RNA was extracted and cDNA was synthesized. Quantitative real-time PCR (qPCR) was performed for the two genes involved in neuronal iron uptake (Tfr1 and Slc11a2), as a functional readout of neuronal iron status. Relative mRNA levels are calculated relative to an internal control cDNA sample and a reference gene (i.e. Tbp). The data from two to three independent cultures were pooled and are presented as mean AE SEM (n = 7-12 per group). Groups not sharing a common letter (a > b > c) are significantly different by Kruskal-Wallis non-parametric test and Dunn's multiple comparison (P < 0.05). d indicates a trend towards increased Slc11a2 compared with controls (P = 0.08). . Eltrombopag (ELT) impairs expression of genes involved in neuronal maturation and synaptic function. Hippocampal neuron cultures were treated with ELT or deferoxamine at 7 days in vitro (DIV) (see Fig. 1 ). At 14 DIV, cells were collected, total RNA was extracted and cDNA was synthesized. Quantitative real-time PCR (qPCR) was performed for genes involved in neuronal and synaptic development, function and plasticity (i.e. BdnfVI, Camk2a and Vamp1). Relative mRNA levels are calculated relative to an internal control cDNA sample and a reference gene (i.e. Tbp). The data from two to three independent cultures were pooled and are presented as mean AE SEM (n = 7-12 per group).
Groups not sharing a common letter (a > b > c) are significantly different by Kruskal-Wallis non-parametric test and Dunn's multiple comparison (P < 0.05).
pyramidal neuron apical dendrite length, the average length of the longest dendrite was 15% and 13% shorter in ELT-and DFO-treated neurons, respectively (Fig. 7A) . Overall, the primary dendrites were 12% shorter for ELT-treated neurons, which was similar to the non-significant trend towards reduced primary dendrite length for the DFO-treated neurons (Fig. 7B) . The number of primary dendrites was not altered by either treatment (Fig. 7C) . The average length of branches was 17% and 22% shorter in DFO-and 6 lM ELT-treated neurons (Fig. 8A) . ELT and DFO treatments had a similar effect on the length of both secondary and tertiary branches (Fig. 8B, C) . The number of secondary and tertiary branches as well as the total number of branches per neuron was reduced by ELT but not DFO (Fig. 8D, E, F) .
Discussion
Our findings demonstrate that ELT, a thrombopoietic agent that is being utilized more frequently for treatment of thrombocytopenia in children, crosses an in vitro BBB and can induce ID in developing hippocampal neurons.
The change in neuronal iron status induced by ELT was associated with typical dendrite structural and gene changes that have been described with ID alone. More simplistic branching patterns with truncation of dendritic lengths resulted from ELT exposure, along with downregulation of genes that are critical for neurodevelopment, synaptic function and neuronal plasticity.
These studies were prompted by a number of concurrent observations: (i) some neonates experience prolonged and persistent thrombocytopenia and might be candidates for therapy with ELT [31] ; (ii) ELT was recently approved for use in children and it has been increasingly shown to be effective in a variety of thrombocytopenias that can present in infancy and early childhood [7] [8] [9] [10] , thus, it is likely that it might be considered as a potential therapy in younger infants with these disorders; (iii) Roth et al. demonstrated that ELT is a potent intracellular iron chelator and that this effect mediates its antiproliferative effect on leukemic cells [11] ; (iv) we recently observed that ELT also had dose-dependent and iron status-dependent effects on cord blood-derived megakaryocytes, which also rely on their rapid proliferation to maintain platelet production (M Sola-Visner unpublished observations); and (v) the brain is highly susceptible to iron deprivation during the first 2 years of life and early-life ID leads to longlasting neurocognitive deficits.
In the current study, we exposed primary hippocampal neuron cultures to a concentration of ELT (6 lM, equivalent to 2.7 lg mL
À1
) that is at the low end of the range achieved in adults with clinically used doses. Although no pharmacokinetic studies of ELT have been conducted in pediatric patients, doses of 150 mg day À1 in adults resulted in steady state ELT concentrations of 22.8 lg mL À1 or 51.5 lM [32] . The comparison dose of DFO was calibrated based on previous studies [22] to induce the degree of brain ID documented in neonates [33, 34] , in preclinical models of dietary ID anemia in the neonatal rat pup [35] [36] [37] and in a non-anemic genetic mouse model of neuron-specific ID [19] . The standard maternal-fetal dietary iron restriction rodent model induces a similar degree of reduction in brain iron concentration and is accompanied by a 1.5 9 to 2 9 increase in Tfr1 and Slc11a2 gene expression in the neonatal hippocampus [35] . A similar degree of Tfr1 elevation is found in a transgenic mouse model of hippocampal neuron-specific iron deficiency [19] . All of the preclinical ID models demonstrate significant impairments in neuronal synaptic transmission and hippocampal-dependent behaviors and are also characterized by the same significant dendritic structural and gene expression alterations that we found in both the ELT and DFO-treated neurons in this study [19, 20, 22, 37, 38] . Importantly, these early-life impairments persist into adulthood in spite of iron repletion. ELT treatment induced Tfr1 mRNA to a similar level to that seen in our early-life ID in vitro and in vivo models. We speculate based on these equivalency calculations, that 6-lM concentrations of ELT in the central nervous system (CNS) during a critical period of brain development could cause significant neuronal ID and long-term structural/functional abnormalities. Eltrombopag is administered orally. Thus, penetration of the drug into the CNS will be a function of its ability to cross the BBB. The unique in vitro model of the BBB that we utilized in this study is populated with healthy adult BBB endothelial cells and was used to show proof of concept that ELT crosses the barrier. P-glycoprotein, the major BBB endothelial cell drug exporter, is expressed in our BBB model [39] . This, together with our findings that ELT crosses BBB endothelial cells, The total number of branches per neuron was quantified. Quantification of the total number of (E) secondary and (F) tertiary branches per neuron is shown. Groups not sharing a common letter (a > b > c) are significantly different by one-way ANOVA and Tukey's post-hoc test (P < 0.05). The data from two independent cultures were pooled and are presented as mean AE SEM (n = 73-78 neurons per group). d indicates a trend towards decreased tertiary branch length compared with controls (P = 0.06).
indicates that the BBB will not actively exclude eltrombopag. The ELT transport data also suggest that there is not free passage and that concentrations found in the brain will be lower than in the serum in the adult. However, the amount of transport (2.79%) observed in an intact adult BBB setting might under-represent the maximum potential for ELT transport in neonates or infants. In our cytotoxicity studies, endothelial cell death was observed at ELT concentrations that are within the clinically observed range (data not shown). No data are currently available on CNS permeability to ELT in neonates. The patency of the BBB in the neonate has been long debated with respect to how permeable it is, and for how long into the postnatal period it remains different to that of the adult [40] . Thus, BBB permeability in neonates and young children may vary considerably based on the properties of the compound to be transported, the age of the child and the child's illness. An important next step will be to assess the in vivo brain uptake of ELT.
In summary, before ELT is utilized extensively for neonates or infants up to 2 years of age who are in a phase of rapid brain development, in vivo preclinical studies need to be performed to determine an optimal peripheral concentration that stimulates thrombopoiesis without causing tissue ID. In particular, the kinetics of ELT transport across the neonatal BBB will need to be considered in order to avoid brain ID and its associated long-term functional consequences. 
